Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Korian Capital/Financing Update 2015

Jan 26, 2015

1465_rns_2015-01-26_7a2efa22-6983-476e-a215-70f730820425.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

PRESS RELEASE

Paris, 26 January 2015.

Semi-annual report on the liquidity contract as at 31 December 2014

Under the liquidity contract signed by Korian – Medica with ODDO Corporate Finance, the following assets were held in the liquidity account as at 31 December 2014:

  • 23,756 Korian Medica shares;
  • €3,755,883.74.

As at 30 June 2014, date of the last semi-annual report, the following assets were held in the liquidity account:

  • 95,601 Korian Medica shares;
  • €1,711,983.31.

ABOUT KORIAN – MEDICA

Korian – Medica, European leading Ageing Well specialist, founded in 2003, has the capacity to accommodate more than 57,500 residents and patients in Europe (France, Germany, Italy and Belgium) and employs around 40,000 staff members. The Group manages 509 nursing homes and 87 specialist follow-up care and rehabilitation clinics, has over 2,400 beds in assisted living facilities and provides home-care services for over 9,000 customers.

For more information, please visit the website: www.groupe-korian.com

Korian – Medica has been listed on Euronext Paris Compartment B since November 2006 and is included in the following indices: SBF 120, CAC Health Care, CAC Mid 60, CAC Mid & Small and MSCI Global Small Cap

Euronext ticker: KORI - ISIN: FR0010386334 – Reuters: KORI.PA – Bloomberg: KORI.FP

INVESTOR CONTACTS

KORIAN – MEDICA

Jean-Brieuc Le Tinier Chief Financial Officer [email protected] Tel: +33 (0)1 55 37 52 29

Didier Laurens Investor Relations [email protected] Tel: +33 (0)1 55 37 53 55